Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Iovance Biotherapeutics. The associated price target remains the same with $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyler Van Buren’s rating is based on a combination of factors that suggest potential growth for Iovance Biotherapeutics despite recent revenue shortfalls. The company reported a total Q2 revenue of $60 million, which was a 10% miss from consensus expectations, primarily due to lower-than-expected Proleukin sales. However, the revenue from Amtagvi was in line with expectations, showing a 24% quarter-over-quarter growth, which indicates a solid performance in that segment.
Despite the challenges, Iovance Biotherapeutics has reiterated its 2025 revenue guidance of $250-300 million, reflecting confidence in future growth driven by increased uptake within ATCs and community referrals. The company is also taking strategic steps to enhance prescribing depth by partnering with a specialty pharmacy, which could boost future sales. These factors, along with the projected revenue growth, underpin Tyler Van Buren’s Buy rating, suggesting that the stock has the potential for appreciation as the company executes its growth strategy.
Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, Moderna, and Soleno Therapeutics. According to TipRanks, Van Buren has an average return of -2.2% and a 41.79% success rate on recommended stocks.
In another report released on July 25, Barclays also maintained a Buy rating on the stock with a $4.00 price target.